Phase 1 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to take part voluntarily, understand the study procedures, and sign a consent form
• Adults aged 18 to 75 years, of any gender
• People who have been diagnosed with an advanced solid tumour (confirmed by laboratory testing of tissue or cells) whose cancer has not responded to standard treatments, or for whom no standard treatment is available
• People who have at least one tumour that can be measured using standard imaging criteria (called RECIST v1.1)
• People who are generally well enough to carry out light activity — rated 0 or 1 on a standard health performance scale (ECOG)
• People with liver cancer (hepatocellular carcinoma) whose liver function scores at a certain level or below on the Child-Pugh scale (score of 7 or less)
• People whose doctors estimate they are likely to live for at least 3 more months
• People whose blood counts and organ function (including liver, kidneys, and heart/lungs) meet specific minimum levels as determined by blood tests
• People who are able to provide a tumour tissue sample (either freshly collected or previously stored) for research testing, where possible
• People who are capable of having children (male or female) must agree to use effective contraception from signing the consent form until at least 90 days after the last dose of the study drug; women capable of becoming pregnant must have a negative blood pregnancy test within 7 days before the first dose

Who may not be able to join:

• People who have received another clinical trial treatment, chemotherapy, radiotherapy, or similar systemic cancer treatment within 28 days (or 5 half-lives of that treatment, whichever is shorter) before the first dose; or who have used herbal or Chinese medicines with anti-tumour purposes within 2 weeks before the first dose
• People who had surgery or a serious injury within 4 weeks before the first dose
• People who have been taking high-dose steroid medications (such as prednisone above 10 mg/day or a similar amount of another steroid) or other immune-suppressing medicines within 2 weeks before the first dose
• People who have received immune-system-modifying drugs within 2 weeks before the first dose
• People who received a live vaccine within 4 weeks before the first dose
• People who have previously been treated with certain targeted cancer therapies, specifically those that work against PD-1, PD-L1, CTLA-4, or VEGF (confirm with trial site if unsure whether a prior treatment falls into these categories)
• People who still have unresolved side effects from previous cancer treatments that have not improved to a mild level (Grade 1 or lower on a standard medical scale)
• People who had to permanently stop a previous immunotherapy due to immune-related side effects, or who experienced severe (Grade 3 or higher) side effects from a previous anti-blood-vessel-growth therapy
• People who have previously had a bone marrow transplant or an organ transplant from another person
• People with active cancer spread to the brain, cancer spread to the lining of the brain or spinal cord, spinal cord compression, or a related condition called molluscum contagiosum disease
• People who have had another separate cancer diagnosed within the past 5 years — with exceptions for certain skin cancers, papillary thyroid cancer, or pre-cancerous conditions that were fully treated
• People with an active autoimmune disease, or a history of autoimmune disease
• People with certain active infections, including active hepatitis B or C (with some exceptions based on specific test results — confirm with trial site), HIV/AIDS, active syphilis, active tuberculosis, or any active infection within 2 weeks before the first dose
• People with serious unstable health conditions, including severe heart or blood vessel disease, or fluid build-up around the lungs, heart, or abdomen that requires repeated draining
• People with serious bleeding problems or blood clotting disorders
• People with a history of non-infectious lung inflammation or scarring that required steroid treatment
• People who are pregnant or breastfeeding
• People whom the trial doctor considers unsuitable for the study for any reason
• People who have previously had a serious allergic reaction to any ingredient in the study drug HC010

Important: Always verify eligibility with the trial site directly before applying.